Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7383296 | 0.95 | EDNRB (0.90) | EDNRBEDNRA | |
| SCHEMBL8684553 | 0.90 | EDNRA (0.81) | EDNRBEDNRA | |
| SCHEMBL6638622 | 0.89 | EDNRB (1.00) | EDNRBEDNRA | |
| SCHEMBL6640830 | 0.85 | EDNRB (1.00) | EDNRBEDNRA | |
| SCHEMBL6703895 | 0.83 | EDNRA (0.71) | EDNRBEDNRA | |
| SCHEMBL6975042 | 0.80 | EDNRB (0.66) | EDNRBEDNRA | |
| SCHEMBL8684737 | 0.79 | EDNRB (0.82) | EDNRBEDNRA | |
| SCHEMBL6644613 | 0.79 | EDNRB (0.80) | EDNRBEDNRA | |
| SCHEMBL6540714 | 0.77 | EDNRA (0.63) | EDNRBEDNRA | |
| SCHEMBL26552022 | 0.77 | EDNRA (0.76) | EDNRBEDNRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0996618-B1 | ENDOTHELIN ANTAGONISTS: N- 2'- (4,5-DIMETHYL-3-ISOXAZOLYL) AMINO]SULFONYL]-4-(2-OXAZOLYL) 1,1'-BIPHENYL]-2-YL]METHYL] -N,3,3-TRIMETHYLBUTANAMIDE AND N-(4,5-DIMETHYL-3-ISOXAZOLYL) -2'- (3,3-DIMETHYL-2-OXO-1-PYRROLIDINYL) METHYL] -4'-(2-OXAZOLYL) 1,1'-BIPHENYL]-2-SULFONAMIDE AND SALTS THEREOF | BRISTOL MYERS SQUIBB CO (US) | 2003-11-12 | — | — | EP | claimed |
| US-6268388-B1 | ADMINISTERING A BIPHENYL SULFONAMIDE | BRISTOL-MYERS SQUIBB COMPANY | 2001-07-31 | — | — | US | claimed |
| EP-0996618-A1 | ENDOTHELIN ANTAGONISTS: N- 2'- (4,5-DIMETHYL-3-ISOXAZOLYL) AMINO]SULFONYL]-4-(2-OXAZOLYL) 1,1'-BIPHENYL]-2-YL]METHYL] -N,3,3-TRIMETHYLBUTANAMIDE AND N-(4,5-DIMETHYL-3-ISOXAZOLYL) -2'- (3,3-DIMETHYL-2-OXO-1-PYRROLIDINYL) METHYL] -4'-(2-OXAZOLYL) 1,1'-BIPHENYL]-2-SULFONAMIDE AND SALTS THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-05-03 | — | — | EP | claimed |
| EP-0996618-A4 | ENDOTHELIN ANTAGONISTS: N- 2'- (4,5-DIMETHYL-3-ISOXAZOLYL) AMINO]SULFONYL]-4-(2-OXAZOLYL) 1,1'-BIPHENYL]-2-YL]METHYL] -N,3,3-TRIMETHYLBUTANAMIDE AND N-(4,5-DIMETHYL-3-ISOXAZOLYL) -2'- (3,3-DIMETHYL-2-OXO-1-PYRROLIDINYL) METHYL] -4'-(2-OXAZOLYL) 1,1'-BIPHENYL]-2-SULFONAMIDE AND SALTS THEREOF | BRISTOL MYERS SQUIBB CO (US) | 2000-05-03 | — | — | EP | claimed |
| US-6043265-A | TREATING HYPERTENSION, PULMONARY HYPERTENSION, BENIGN PROSTATIC HYPERTROPHY, MIGRAINE, UROGENITAL DISORDERS, ENDOTOXEMIA, ISCHEMIA, ATHEROSCLEROSIS, RESTENOSIS, SUBARACHNOID HEMORRHAGE, CONGESTIVE HEART FAILURE | BRISTOL-MYERS SQUIBB CO. (US) | 2000-03-28 | — | — | US | claimed |
| WO-1998033780-A1 | ENDOTHELIN ANTAGONISTS: N-[[2'-[ [(4,5-DIMETHYL-3-ISOXAZOLYL) AMINO]SULFONYL]-4-(2-OXAZOLYL) [1,1'-BIPHENYL]-2-YL]METHYL] -N,3,3-TRIMETHYLBUTANAMIDE AND N-(4,5-DIMETHYL-3-ISOXAZOLYL) -2'-[(3,3-DIMETHYL-2-OXO-1-PYRROLIDINYL) METHYL] -4'-(2-OXAZOLYL)[1,1'-BIPHENYL]-2-SULFONAMIDE AND SALTS THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-08-06 | — | — | WO | claimed |
| US-10828368-B2 | Therapeutic treatments using centhaquin | MIDWESTERN UNIVERSITY (US) | 2020-11-10 | — | — | US | disclosed |
| US-20180085461-A1 | Novel Therapeutic Treatments Using Centhaquin | MIDWESTERN UNIVERISTY | 2018-03-29 | — | — | US | disclosed |
| EP-2424530-B1 | METHOD AND COMPOSITION FOR TREATING DIABETIC KETOACIDOSIS | UNIV MIDWESTERN (US) | 2015-12-16 | — | — | EP | disclosed |
| US-8980874-B2 | Method and composition for treating diabetic ketoacidosis | MIDWESTERN UNIVERSITY (US) | 2015-03-17 | — | — | US | disclosed |
| US-20130225531-A1 | METHOD AND COMPOSITION FOR TREATING ALZHEIMER'S DISEASE AND DEMENTIAS OF VASCULAR ORIGIN | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2013-08-29 | — | — | US | disclosed |
| US-8410148-B2 | Method and composition for potentiating an opiate analgesic | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2013-04-02 | — | — | US | disclosed |
| US-8410148-B2 | Method and composition for potentiating an opiate analgesic | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2013-04-02 | — | — | US | disclosed |
| US-6043265-A | TREATING HYPERTENSION, PULMONARY HYPERTENSION, BENIGN PROSTATIC HYPERTROPHY, MIGRAINE, UROGENITAL DISORDERS, ENDOTOXEMIA, ISCHEMIA, ATHEROSCLEROSIS, RESTENOSIS, SUBARACHNOID HEMORRHAGE, CONGESTIVE HEART FAILURE | BRISTOL-MYERS SQUIBB CO. (US) | 2000-03-28 | — | — | US | disclosed |
| CN-1244862-A | Endothelin antagonists N- [ [2' - [ [ (4, 5-dimethyl-3-isoxazolyl) amino ] sulfonyl ] -4- (2-oxazolyl) [1,1' biphenyl ] -2-yl ] methyl ] -N, 3, 3-trimethylbutanamide and N- (4, 5-dimethyl-3-isoxazolyl) -2 ' - [3, 3-dimethyl-2-oxo-1-pyrrolidinyl) methyl ] -4 ' -2-oxazolyl) [1,1' -biphenyl ] -2-sulfonamide and salts thereof | BRISTOL MYERS SQUIBB CO (US) | 2000-02-16 | — | — | CN | disclosed |
| US-5916907-A | Method for preventing or treating low renin hypertension by administering an endothelin antagonist | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-06-29 | — | — | US | disclosed |
| WO-1998033780-A1 | ENDOTHELIN ANTAGONISTS: N-[[2'-[ [(4,5-DIMETHYL-3-ISOXAZOLYL) AMINO]SULFONYL]-4-(2-OXAZOLYL) [1,1'-BIPHENYL]-2-YL]METHYL] -N,3,3-TRIMETHYLBUTANAMIDE AND N-(4,5-DIMETHYL-3-ISOXAZOLYL) -2'-[(3,3-DIMETHYL-2-OXO-1-PYRROLIDINYL) METHYL] -4'-(2-OXAZOLYL)[1,1'-BIPHENYL]-2-SULFONAMIDE AND SALTS THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-08-06 | — | — | WO | disclosed |
| WO-1998033780-A1 | ENDOTHELIN ANTAGONISTS: N-[[2'-[ [(4,5-DIMETHYL-3-ISOXAZOLYL) AMINO]SULFONYL]-4-(2-OXAZOLYL) [1,1'-BIPHENYL]-2-YL]METHYL] -N,3,3-TRIMETHYLBUTANAMIDE AND N-(4,5-DIMETHYL-3-ISOXAZOLYL) -2'-[(3,3-DIMETHYL-2-OXO-1-PYRROLIDINYL) METHYL] -4'-(2-OXAZOLYL)[1,1'-BIPHENYL]-2-SULFONAMIDE AND SALTS THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-08-06 | — | — | WO | disclosed |
| WO-1998033780-A1 | ENDOTHELIN ANTAGONISTS: N-[[2'-[ [(4,5-DIMETHYL-3-ISOXAZOLYL) AMINO]SULFONYL]-4-(2-OXAZOLYL) [1,1'-BIPHENYL]-2-YL]METHYL] -N,3,3-TRIMETHYLBUTANAMIDE AND N-(4,5-DIMETHYL-3-ISOXAZOLYL) -2'-[(3,3-DIMETHYL-2-OXO-1-PYRROLIDINYL) METHYL] -4'-(2-OXAZOLYL)[1,1'-BIPHENYL]-2-SULFONAMIDE AND SALTS THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-08-06 | — | — | WO | disclosed |
| WO-1998033781-A1 | METHOD FOR PREVENTING OR TREATING LOW RENIN HYPERTENSION BY ADMINISTERING AN ENDOTHELIN ANTAGONIST | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10828368-B2 | Therapeutic treatments using centhaquin | ADRA2A, ADRB3, HSPH1 | EDNRB 502/4885EDNRA 429/4885 |
| US-20130225531-A1 | METHOD AND COMPOSITION FOR TREATING ALZHEIMER'S DISEASE AND DEMENTIAS OF VASCULAR ORIGIN | PSEN1, PSEN2, CHAT | EDNRB 7/4885EDNRA 11/4885 |
| US-20180085461-A1 | Novel Therapeutic Treatments Using Centhaquin | ADRB3, ADRA2A, ADRB2 | EDNRB 148/4885EDNRA 141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.